Although RA-specific GLP-1 nanotherapeutics remain under development, albumin NPs have shown efficacy as carriers
Retrieved from GoodRx-m
The retatrutide triple agonist GLP-1 GIP glucagon mechanism works through three parallel axes: GLP-1 receptor activation: Stimulates glucose-dependent insulin secretion from pancreatic beta cells, suppresses glucagon release from alpha cells, slows gastric emptying, and reduces appetite signalling in the hypothalamus
Your healthcare provider can determine whether a dosage change is appropriate based on your overall health and response to the medication
GLP-1RAs directly stimulate POMC/CART neurons and indirectly inhibit NPY and AgRP to increase measures of satiety and decrease hunger, resulting in reduced energy intake, thereby facilitating weight loss (Ard et al., 2021) (Figure 6)
Patients need to take them whole with a sip of water on an empty stomach after fasting for at least eight hours, then avoid food or drink for at least 30 minutes